RG7667

for prevention of cytomegalovirus infection; in phase 2 cllnical trials (2017)

Networked: 4 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Blood Proteins: 12459
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        RG7667: 4
    - Immunoproteins: 43
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        RG7667: 4
  - Globulins: 3062
    - Serum Globulins: 553
      - Immunoglobulins: 30480
        Antibodies: 133716
        Monoclonal Antibodies: 56412
        RG7667: 4

Experts

1.	Deng, Rong: 4 articles (11/2018 - 08/2015)
2.	Burgess, Tracy: 3 articles (01/2018 - 08/2015)
3.	Liao, X Charlene: 3 articles (01/2018 - 08/2015)
4.	Maia, Mauricio: 3 articles (01/2018 - 08/2015)
5.	Tavel, Jorge A: 3 articles (01/2018 - 08/2015)
6.	McBride, Jacqueline M: 2 articles (01/2018 - 01/2017)
7.	Derby, Michael A: 2 articles (01/2017 - 08/2015)
8.	Emu, Brinda: 2 articles (01/2017 - 08/2015)
9.	Feierbach, Becket: 2 articles (01/2017 - 08/2015)
10.	Fouts, Ashley E: 2 articles (01/2017 - 08/2015)

Related Diseases

1.	Cytomegalovirus Infections (Inclusion Disease) 08/01/2015 - "This study supports further development of RG7667 as a therapy for the prevention and treatment of cytomegalovirus infection in susceptible populations. " 01/01/2018 - "Pharmacokinetics and Exposure-Response Analysis of RG7667, a Combination of Two Anticytomegalovirus Monoclonal Antibodies, in a Phase 2a Randomized Trial To Prevent Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients." 01/01/2017 - "Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of RG7667, a Combination Monoclonal Antibody, for Prevention of Cytomegalovirus Infection in High-Risk Kidney Transplant Recipients."
2.	Infections 01/01/2018 - "RG7667 was assessed for preventing CMV infection in a phase 2a trial with CMV-seronegative recipients of kidney transplants from CMV-seropositive donors. " 01/01/2017 - "In high-risk kidney transplant recipients, RG7667 was well tolerated, numerically reduced the incidence of CMV infection within 12 and 24 weeks posttransplant, delayed time to CMV viremia, and was associated with less CMV disease than the placebo. " 01/01/2017 - "We examined the ability of RG7667, a combination of two monoclonal antibodies, to prevent CMV infection in high-risk kidney transplant recipients in a randomized, double-blind, placebo-controlled trial. "
3.	Viremia 01/01/2017 - "Median time to CMV viremia was 139 days in patients receiving RG7667 compared to 46 days in patients receiving placebo (hazard ratio, 0.53; P = 0.009). " 01/01/2017 - "CMV viremia occurred in 27 of 59 (45.8%) patients receiving RG7667 and 35 of 57 (61.4%) patients receiving placebo (stratum-adjusted difference, 15.3%; P = 0.100) within 12 weeks posttransplant and in 30 of 59 (50.8%) patients receiving RG7667 and 40 of 57 (70.2%) patients receiving placebo (stratum-adjusted difference, 19.3%; P = 0.040) within 24 weeks posttransplant. " 01/01/2018 - "Patients with RG7667 or component antibody exposures greater than the respective median values had a lower incidence of viremia at 12 weeks and 24 weeks after transplantation and a longer delayed time to detectable CMV viremia than patients with exposures less than the median values. " 01/01/2017 - "In high-risk kidney transplant recipients, RG7667 was well tolerated, numerically reduced the incidence of CMV infection within 12 and 24 weeks posttransplant, delayed time to CMV viremia, and was associated with less CMV disease than the placebo. "
4.	Necrosis 11/01/2018 - "However, at cesarean section, hepatic necrosis and pancreatic edema were identified in two dams administered RG7667, with no clear dose relationship. "
5.	Edema (Dropsy) 11/01/2018 - "However, at cesarean section, hepatic necrosis and pancreatic edema were identified in two dams administered RG7667, with no clear dose relationship. "

Related Drugs and Biologics

1.	Monoclonal Antibodies

Related Therapies and Procedures

1.	Therapeutics
2.	Transplantation
3.	Cesarean Section (Caesarean Section)